
April 1 (Reuters) - GRI Bio Inc GRI.O:
GRI BIO REPORTS ENCOURAGING INTERIM 2-WEEK SAFETY RESULTS FROM ONGOING PHASE 2A STUDY OF GRI-0621 IN IDIOPATHIC PULMONARY FIBROSIS (“IPF”)
GRI BIO INC - IDMC RECOMMENDS CONTINUATION OF STUDY WITH NO SAFETY CONCERNS
GRI BIO INC - GRI-0621 SAFE AND WELL-TOLERATED IN FIRST 12 PATIENTS
GRI BIO INC - INTERIM BIOMARKER DATA EXPECTED Q2 2025, TOPLINE RESULTS Q3 2025